Satellos Bioscience Inc. (MSCLF)
Satellos Bioscience Inc.
Royal Bank Plaza
Suite 2800 South Tower 200 Bay Street
Toronto, ON M5J 2J1
Canada
https://satellos.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, President & Director | 592.52k | N/D | 1955 |
| Ms. Elizabeth Williams CA, CPA | CFO & Corporate Secretary | 250.56k | N/D | 1978 |
| Dr. Philip Lambert M.A., Ph.D. | Chief Scientific Officer | 633.45k | N/D | 1969 |
| Mr. William Wasyl Jarosz | Executive Director | 136.91k | N/D | 1956 |
| Mr. Warren Whitehead C.M.A., CPA | Head of Corporate Strategy | 229.63k | N/D | 1952 |
| Dr. Michael Cross M.B.A., Ph.D. | Chief Business Officer | 253.45k | N/D | 1965 |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Discovery Officer | 87.89k | N/D | 1962 |
| Mr. J. Robert Hall CFA | Senior Vice President of Finance & Administration | N/D | N/D | N/D |
| Dr. Ryan Mitchell Ph.D. | Vice President of Corporate Development | N/D | N/D | N/D |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor | 32.58k | N/D | 1960 |
Descripción
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Satellos Bioscience Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
